Kinnos – the maker of Highlight, a novel technology that colorizes disinfectants – announced a $15 million financing led by a group of current and former industry leaders. And the company also named healthcare veteran Steve Fanning as Chief Executive Officer and a member of the Board of Directors.
This latest funding round and new leadership will enable the company to scale to meet growing healthcare industry demand for Highlight, its patented portfolio of products for improving cleaning and safety by visibly coloring the disinfectants hospitals currently use. The current and new investors include family offices and funds like Pioneer Healthcare Partners, Kapor Center, and Partnership Fund for NYC and former industry leaders from Abbott, Baxalta, Baxter, Bayer, Becton Dickinson, Cantel, Ecolab, Intermountain Healthcare, NorthShore University HealthSystem, and Walgreens, among others.
Fanning arrives at Kinnos from Henry Schein where oversaw the Endodontics and Restoratives businesses. And for the two decades prior, he held leadership roles at Johnson & Johnson and Danaher where he served as the VP and GM of its Infection Prevention portfolio.
Launched during the Ebola outbreak in West Africa in 2015, Kinnos has steadily expanded its family of solutions at a time when disinfection and cleaning are paramount. And following the COVID-19 global pandemic, Kinnos has tapped Fanning and a seasoned cadre of investors to fuel rapid growth amidst urgent demand for more effective disinfection.
With this latest funding round, Kinnos is poised to establish a new standard of care for cleanliness in healthcare and beyond.
KEY QUOTE:
“Cleaning, disinfection, and safety are mission-critical concerns for every hospital leader today. Highlight from Kinnos empowers those charged with cleaning and disinfecting to better see the results of their efforts, enhancing confidence and peace of mind around effectively performing their jobs and serving our most vulnerable communities.”
— Steve Fanning
